Global CNS Therapeutics Market Report 2022 - CNS Therapeutics Exhibit Robust Opportunities amidst Rising Incidence of CNS Disorders

News provided by

Mar 22, 2022, 09:45 ET

DUBLIN, March 22, 2022 /PRNewswire/ -- The "CNS Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global CNS Therapeutics Market to Reach $132.1 Billion by 2024

Amid the COVID-19 crisis, the global market for CNS Therapeutics is projected to reach US$132.1 Billion by 2024, registering a compounded annual growth rate (CAGR) of 5.1% over the analysis period. The United States represents the largest regional market for CNS Therapeutics, accounting for an estimated 50.2% share of the global total. The market is projected to reach US$70 Billion by the end of the analysis period. China is expected to spearhead growth and emerge as the fastest growing regional market with a CAGR of 7.1% over the analysis period.

The market is on a growth trajectory led by increasing incidence of CNS diseases, rapidly growing aging population, and rising healthcare expenditure. Unmet healthcare needs for detecting and treating CNS conditions brings to fore the untapped potential in the market. Presently, there exists increased demand for new laboratory tests to monitor CNS diseases and also an urgent requirement for developing safe and effective drugs that overthrow limitation of current generation drugs. Companies are therefore investing to develop novel drugs in the neurodegenerative segment. The industry has crossed some milestones in recent years with regard to developing therapies with relatively lesser side effects, convenient drug administration, and efficient performance, although major breakthroughs are still in pipeline. In addition to the reduction in prices in general as a result of patent expiries and the generication of the drugs market, the growing confidence in drug efficacy and clinical evidences is also offering a strong business case for these drugs.

Greater patient compliance as a result of increased awareness about the benefits of the drugs, such as improved quality of life and reduction/prevention of disease co-morbidity, will also help spur patient adherence to prescribed treatment regimes. Acceptance of new therapies and new classes of drugs will additionally benefit the market. In the anti-epilepsy market, for instance, GABA receptor modulators, sodium channel blockers, AMPA receptor antagonist, glutamate blocker, and CRMP-2 modulator, are growing in popularity. Government intervention, especially in developing countries, geared at improving healthcare infrastructure, also infuses confidence in sporting a bullish outlook for the CNS drugs market. Increasing attention towards regenerative therapies for CNS disorders is among the key trends in the market. Such therapies support in healing by replacing or regenerating tissues or human cells, or organs. Several regenerative therapies, such as growth factors, stem cells, and usage of matrix, such as hyaluronic acid, collagen, and fibrin, are emerging.

Therefore, several companies have been focusing on developing regenerative medicines, supported by product innovations and technological advancements. Several existing and new companies are also seen introducing effective medicines for the treatment of specific ailments. Strategic initiatives and partnerships, and launch of novel drugs are the other trends of the market. CNS drugs, specifically for neurodegenerative diseases, are set to become the next big healthcare movement over the coming decades, with Alzheimer`s and Parkinson`s diseases as the two most important therapeutic categories. Though there exists no curative medicine available at present, medications that provide partial relief from symptoms have gained momentum in the recent past. Growing aging population, rising life expectancy, rising incidences of Parkinson`s and Alzheimer`s diseases are the key growth drivers in the markets. Increased demand for combination therapies and growing usage of generics are important trends in the market. Introduction of new class of Alzheimer`s drugs, including anti-amyloid proteins, anti-tau proteins, cholinergic and nicotine receptor agonists, Neuro protective drugs, and GABA receptor modulators, will also help support growth in this space.

The market is also witnessing the launch of novel therapies for the treatment of Parkinson`s disease, such as adenosine and andrenergic agonists, glutamate receptor modulators, and dopamine receptor agonists. Other disease conditions propelling increases in CNS prescriptions, although to a lesser extent, include pain manifestations, psychiatric disorders (schizophrenia, sleep disorders, depression and anxiety), cerebrovascular disorders, stroke, seizures, cognitive and memory disorders, and ailments caused due to injuries and physical trauma.

Select Competitors (Total 181 Featured)

AbbVie Inc.
Alkermes plc
Allergan plc
AstraZeneca plc
Bristol-Myers Squibb
Eisai Co. Ltd.
Eli Lilly and Co.
Endo Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
H. Lundbeck A/S
Janssen Pharmaceuticals Inc.
Merck & Co. Inc.
Neurocrine Biosciences, Inc.
Novartis AG
Otsuka Pharmaceutical Co. Ltd.
Pfizer Inc.
Purdue Pharma L.P.
Sanofi
Shire plc
Sumitomo Dainippon Pharma Co. Ltd.
Takeda Pharmaceutical Co. Ltd.
Teva Pharmaceutical Industries Ltd.
UCB Group

Key Topics Covered

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Central Nervous System (CNS) Therapeutics: A Prelude
CNS Therapeutics Exhibit Robust Opportunities amidst Rising Incidence of CNS Disorders
List of FDA Approved CNS Drugs: 2019
List of FDA Approved CNS Drugs: 2018
Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market
Patent Expiries of Leading CNS Drugs: 2008-2022
Developed Markets to Maintain their Dominance
Developing Market to Drive the Market Momentum
CNS Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Market Analysis by Therapeutic Category
Anti-Epilepsy Market
Global Market Overview
Regional Landscape
Developed Countries Account for a Major Share of Epilepsy Treatment
Developing Countries Struggle with Low Treatment Rates
New Approvals (2019 and 2018)
Disease Overview
Epilepsy Incidence by Type (2019): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy
Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy
High Unmet Needs Offer Scope for Market Growth
Treatment
Anti-Epileptic Drugs (AEDs) by Generic Name and Brand Names
Leading Anti-Epileptic Drugs
Leading Anti-Epileptic Drugs and Their Mechanism of Action
Patent Expiries of Major Anti-Epilepsy Drugs
FDA's New Policy for AED Drugs to Bolster Market Growth
AAN Updated Guidelines on New AEDs Use for Treating New Onset Epilepsy (2019)
Select Currently Available Epilepsy Drugs
Select Anti-Epilepsy Drugs (AEDs) in Phase III Trials
Innovative Drugs Needed for Better Treatment Compliance
Abounding Potential for NCEs
A New Research Demonstrates Effectiveness of Gluconate in Treating Neonatal Seizures
FDA Approves Epidiolex (Cannabidiol) - First Drug for Treating Dravet Syndrome and Lennox-Gastaut Syndrome
Refractory Childhood Epilepsy & Pregnancy Epilepsy - Major Concerns
Recent Approvals for Childhood Epilepsy: 2016-2019
Review of Anti-Epilepsy Drugs
CNS Pain Management: Market Overview
Treatment
Drugs Indicated for Pain Management
Select Phase III Ongoing Studies for Cancer Pain
Regional Overview
Players
Combination Therapies Gain Prominence
Key Trends in Chronic Pain Management
Neuropathic Pain Management: Market with High Potential
Select Phase III Ongoing Studies for Neuropathic Pain
Lyrica's Generics Gain FDA Approval
Migraine Market: A Core Vertical in CNS Pain Management
Migraine Care: Select Patent Expiries (2013-2015)
Migraine Completed Phase III Studies: As of October 2019
Migraine Ongoing Phase III Studies: As of October 2019
Select Pain Management Drugs
Novartis Presents New Data for Aimovig
Reyvow, Eli Lilly's Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
Three New Migraine Drugs Obtain FDA Approval
Eli Lilly's Emgality Receives FDA Approval
Anti-Alzheimer's: Market Overview
Global Alzheimer's Prevalence by Age Group
Alzheimer's Phase III Completed Studies
Alzheimer's Phase III Ongoing Studies
Treatment for Alzheimer's
Select Leading Drugs for Alzheimer's Disease by Drug Category
Patent Expiries of Leading Alzheimer's Drugs
Aducanumab Marches towards FDA Approval, Following being Abondoned by Biogen a few Months Ago
The Clinical Trials for Aducanumab
Aducanumab: A Promising Drug Which would Revolutionalize the Alzheimer's Market
Alzheimer's Drugs: A Market Plagued with Failures
Promising Compounds with Silver Lining
PRI-002 Gains Success in First Stage of Human Testing for Alzheimer's Disease
Updated FDA Standards Make Way for Increased Alzheimer's Drug Testing
Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
Elenbecestat's Phase 3 Trials Halted
Novel Drug Delivery Method to the Brain Discovered
Alzheimer's Association Provides Grant to Longeveron
A Review of Select Anti-Alzheimer's Drugs
A Review of the Alzheimer's disease
Alzheimer's Effect on Brain
Causes for Alzheimer's
Who Are at Risk?
Prevalence of Alzheimer's Disease
Diagnosis of Alzheimer's
Anti-Parkinson's: Market Overview
Select Top Selling Drugs for Parkinson's Disease
Nourianz, An Add-on Medication for Treating Episodes of Parkinson's Disease Secures FDA Approval
Recent Approvals
Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD
Xadago - Add-On Therapy for Parkinson's Disease
NUPLAZID - The First and the Only Approved Drug for Psychosis related to Parkinson's disease
Parkinson's Phase III Completed Studies: As of October 2019
Parkinson's Ongoing Phase III Studies: As of October 2019
Select Anti-Parkinson's Drugs
FDA Announces Imminent Discontinuation of Certain Formulations of GSK's Requip for PD and RSL Treatment
A Review of the Parkinson's Disease
Anti-Depressants Market Overview
Anti-Depressant Market: Percentage Share Breakdown by Depressive Disorder Type
Anti-Depressant Treatment
Select Top Selling Anti-Depressants in 2018
Select Antidepressants Drugs
Recent Approvals of Anti-Depressants
Esketamine, the Fast Acting Drug for Depression from Janssen Receives FDA Approval
Pipeline Drugs in Phase III for Depressive Disorder: As of October 2019
A Review of Depression
Prevalence of Depression
Causes of Depression
Types of Depressive Disorders
Available Treatment
Tricyclic Antidepressants
Monoamine Oxidase Inhibitors
Lithium Salts
Working of Antidepressants
Ranking of Antidepressants in Terms of Efficacy
Types of Antidepressants
NMDA Receptor Antagonists
NMDA Receptor (NMDAR)
NMDA Receptor Agonists
Acetylcholinesterase Inhibitors
Selective Serotonin Reuptake Inhibitors (SSRIs)
Workings of SSRIs
Safety Levels of SSRI Drugs
Adverse Effects of SSRI
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)
Anti-Psychotics
Market Overview
Leading Atypical Antipsychotics for the Treatment of Schizophrenia
Pipeline Drugs in Phase III for Schizophrenia: As of October 2019
Pipeline Drugs in Phase III for Bipolar Disorder: As of October 2019
Select Anti-Psychotic Drugs
A Review of Anti-Psychotics
Indications of Antipsychotics
An Effective Adjunctive Therapy
Off-label Uses
Efficacy - Marred by Lack of Evidence Base
Types of Antipsychotics
Difference between Typical and Atypical
Atypical Antipsychotics Up Against Typicals
Side Effects of Antipsychotics
Symptoms of Antipsychotics Withdrawal
Bipolar Disorder
Symptoms of Bipolar Disorder
Mood Episode - A Major Symptom
Manic Episode Vs Depressive Episode
Causes of Bipolar Disorder
Types of Bipolar Disorder
Co-morbidities of Bipolar Disorder
Schizophrenia
Prevalence by Gender
Symptoms of Schizophrenia
Causes of Schizophrenia
Other CNS Disorders (Multiple Sclerosis, Attention Deficit Hyperactivity Disorder (ADHD), and Insomnia)
Multiple Sclerosis (MS)
List of Approved Drugs for MS
Patent Expiration Date/Year of the Major MS Drugs
Leading Multiple Sclerosis Drugs (2018): Sales in USD Million
New Approvals
Novartis Receives FDA Approval for Mayzent for Use in Multiple Sclerosis
Mavenclad Gains FDA Approval
Celgene Files NDA for Ozanimod
Ocrevus - The First Approved Drug for Primary Progressive Multiple Sclerosis (PPMS)
Multiple Sclerosis: Pipeline Analysis
Pipeline Drugs in Phase III for Multiple Sclerosis: As of October 2019
A Review of Multiple Sclerosis (MS)
Types of Multiple Sclerosis
Clinical Subtypes of Multiple Sclerosis (MS)
Prevalence of MS
Causes of MS
Myths Surrounding Multiple Sclerosis
Symptoms of MS
Diagnosis of MS
Attention Deficit Hyperactivity Disorder (ADHD)
Market Overview
Approved Drugs for ADHD: 2017
Sales of Vyvanse in 2018
Pipeline Drugs in Phase III for ADHD: As of October 2019
Select ADHD Drugs
A Review of Attention Deficit Hyperactivity Disorder (ADHD)
Consequences of ADHD
What Leads to ADHD?
Insomnia: Overview
List of Approved Drugs for Insomnia
Pipeline Drugs for Insomnia: As of October 2019
A Review of Insomnia
Prevalence of Insomnia
Therapies for Insomnia

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market
Rising Healthcare Expenditure to Boost CNS Therapeutics Market
Growing Middle Class Population in Emerging Regions to Spur the Market
Growing Penetration of Generic Drugs Emerges as a Key Trait
Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market
Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point
Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines
Awareness Campaigns Launched by Pharma Companies to Benefit the Market
Music and Memory Programs Positively Impact Alzheimer's Disease (AD) and Related Dementia (ADRD) Patients
New Method to Isolate Active Compounds Related to Alzheimers from Plant Medicines

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

Total Companies Profiled: 181

For more information about this report visit https://www.researchandmarkets.com/r/ikybqt

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets